102P Clinical analysis of patients with different KRAS mutations in NSCLC: Different entities analyzed by NGS

KRAS mutation is the most common molecular alteration in non-small cell lung cancer (NSCLC), it can be found in up to 25% of patients with adenocarcinoma. However, KRAS mutations represent a heterogeneous group of diseases not well characterized. This could be explained by the genomic commutations or by the type of point mutation that may affect downstream signaling differently. Given the recent discovery of several effective KRAS G12C inhibitors, interest in this type of mutation is on the rise.